Publication:

The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML

Loading...
Thumbnail Image

Date

2010

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

American Association for the Advancement of Science (AAAS)
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Wang, Yingzi, Andrei V. Krivtsov, Amit U. Sinha, Trista E. North, Wolfram Goessling, Zhaohui Feng, Leonard I. Zon, and Scott A. Armstrong. 2010. The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML. Science 327, no. 5973: 1650–1653.

Abstract

Leukemia stem cells (LSCs) are capable of limitless self-renewal and are responsible for the maintenance of leukemia. Because selective eradication of LSCs could offer substantial therapeutic benefit, there is interest in identifying the signaling pathways that control their development. We studied LSCs in mouse models of acute myelogenous leukemia (AML) induced either by coexpression of the Hoxa9 and Meis1a oncogenes or by the fusion oncoprotein MLL-AF9. We show that the Wnt/β-catenin signaling pathway is required for self-renewal of LSCs that are derived from either hematopoietic stem cells (HSC) or more differentiated granulocyte-macrophage progenitors (GMP). Because the Wnt/β-catenin pathway is normally active in HSCs but not in GMP, these results suggest that reactivation of β-catenin signaling is required for the transformation of progenitor cells by certain oncogenes. β-catenin is not absolutely required for self-renewal of adult HSCs; thus, targeting the Wnt/β-catenin pathway may represent a new therapeutic opportunity in AML.

Description

Research Data

Keywords

Terms of Use

Metadata Only

Endorsement

Review

Supplemented By

Related Stories